Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic-MedSci.cn

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic

Kamel, MM; Kutyna, M; Ross, DM; Lane, SW; Thompson-Peach, C; Fong, CY; Yong, ASM; Yeung, DT; Hughes, TP; Hiwase, D; Thomas, D

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务